While precision medicine is streaking ahead in its development and governments are willing to embrace the new treatment options it offers, patent offices are still lagging behind in the protection they can offer. Fran Salisbury of Mewburn Ellis examines the differing attitudes of global patent offices to precision medicine, and considers what companies must be aware of in seeking to protect their IP.